Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-05
2011-04-05
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S443000, C514S469000, C548S494000, C549S058000, C549S469000
Reexamination Certificate
active
07919519
ABSTRACT:
The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
REFERENCES:
patent: 3329781 (1967-07-01), Wiser
patent: 4304785 (1981-12-01), Griengl et al.
patent: 4767896 (1988-08-01), Nigg et al.
patent: 5145865 (1992-09-01), Fujii et al.
patent: 5614531 (1997-03-01), Juraszyk et al.
patent: 5880284 (1999-03-01), Himmelsbach et al.
patent: 6384061 (2002-05-01), Lee et al.
patent: 6411326 (2002-06-01), Tabata
patent: 2002/0156074 (2002-10-01), Barvian et al.
patent: 2002/0183519 (2002-12-01), Nar et al.
patent: 2005/0014725 (2005-01-01), Mi et al.
patent: 2005/0113283 (2005-05-01), Solow-Cordero et al.
patent: 2006/0135786 (2006-06-01), Saha et al.
patent: 2007/0173487 (2007-07-01), Saha et al.
patent: 2008/0015177 (2008-01-01), Saha et al.
patent: 2008/0027036 (2008-01-01), Burli et al.
patent: 2008/0064677 (2008-03-01), Saha et al.
patent: 1 553 075 (2005-07-01), None
patent: 10-204059 (1998-08-01), None
patent: WO 02/064616 (2002-08-01), None
patent: WO 2005/020882 (2003-03-01), None
patent: WO 03/061567 (2003-07-01), None
patent: WO 03/062252 (2003-07-01), None
patent: 03105771 (2003-12-01), None
patent: WO 2004/048383 (2004-06-01), None
patent: WO 2004/062663 (2004-07-01), None
patent: WO 2004/113330 (2004-12-01), None
patent: WO 2005/020882 (2005-03-01), None
patent: 2006064757 (2006-06-01), None
patent: WO 2007/061458 (2007-05-01), None
patent: WO 2007/109330 (2007-09-01), None
patent: WO 2007/109334 (2007-09-01), None
patent: WO 2009/038759 (2009-03-01), None
Pan et al., 2006, “A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model,”Chemistry&Biology, vol. 13:1227-1234.
Traynor et al., 1995, “Modulation by μ-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells,”Molecular Pharmacology, vol. 47:848-854.
Zemann et al., 2006, “Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720,”Blood, 107(4):1454-1458.
PCT International Search Report dated Sep. 20, 2007, for International Application No. PCT/US2006/028657, filed Jul. 24, 2006.
PCT Written Opinion of the International Searching Authority dated Sep. 20, 2007, for International Application No. PCT/US2006/028657, filed Jul. 24, 2006.
PCT International Preliminary Report on Patentability dated May 27, 2008, for International Application No. PCT/US2006/028657, filed Jul. 24, 2006.
PCT International Search Report dated Nov. 12, 2007, for International Application No. PCT/US2006/007044, filed Mar. 21, 2007.
PCT Written Opinion of the International Searching Authority dated Nov. 12, 2007, for International Application No. PCT/US2006/007044, filed Mar. 21, 2007.
U.S. Patent and Trademark Office Non-Final Office Action dated Feb. 25, 2009, for U.S. Appl. No. 11/491,766, filed Jul. 24, 2006.
Abdel-Rahman, T.M., 1998, “Synthesis And Antimicrobial Activity of Some new Thiophene-2-Sulphonyl, Amino Acids and their Peptide Derivatives,” Mans.Sci.Bull. (A Chem.) vol. 25 (1), Jun. 1998.
M.T. Shamin, D. Ukena, W.L. Padgett, O. Hong, J.W. Daley: “8-Zryl- and 8-Cycloalkyl-1,3-dipropylxanthines: Further Potent and Selective Antagonists for A1-Adenosine Receptors,”J. Med. Chem. vol. 31, No. 3, (1988) pp. 613-617.
Becker Oren
Burli Roland
Cee Victor J.
Cheruku Srinivasa R.
Gannon Kimberley
Epix Pharmaceuticals Inc.
Kosack Joseph R
McDonnell Boehnen & Hulbert & Berghoff LLP
LandOfFree
S1P receptor modulating compounds and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S1P receptor modulating compounds and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S1P receptor modulating compounds and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2724503